Symbols / VTVT Stock $33.00 -3.79% vTv Therapeutics Inc.

Healthcare • Biotechnology • United States • NCM
VTVT (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Paul J. Sekhri
Exch · Country NCM · United States
Market Cap 129.98M
Enterprise Value 311.42M
Income 2.25M
Sales 36.84M
FCF (ttm) 5.28M
Book/sh 5.19
Cash/sh 7.90
Employees 26
Insider 10d —
IPO Jul 30, 2015
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -8.48
PEG —
P/S 3.53
P/B 6.35
P/C —
EV/EBITDA -102.64
EV/Sales 8.45
Quick Ratio 14.26
Current Ratio 14.36
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -0.78
EPS next Y -3.89
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-13
Earnings (prior) 2026-05-13
ROA -2.91%
ROE -1.47%
ROIC —
Gross Margin 34.83%
Oper. Margin 63.15%
Profit Margin 6.11%
Shs Outstand 3.94M
Shs Float 2.14M
Insider Own 38.98%
Instit Own 38.35%
Short Float 6.06%
Short Ratio 2.61
Short Interest 144.57K
52W High 44.00
vs 52W High -25.00%
52W Low 14.00
vs 52W Low 135.71%
Beta 0.26
Impl. Vol. —
Rel Volume 0.42
Avg Volume 57.57K
Volume 23.97K
Target (mean) $53.00
Tgt Median $52.00
Tgt Low $44.00
Tgt High $67.00
# Analysts 6
Recom None
Prev Close $34.30
Price $33.00
Change -3.79%
About

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$53.00
Mean price target
2. Current target
$33.00
Latest analyst target
3. DCF / Fair value
$24.12
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$33.00
Low
$44.00
High
$67.00
Mean
$53.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-12 init Evercore ISI Group — → Outperform $44
2026-03-11 reit BTIG Buy → Buy $49
2026-01-27 main BTIG Buy → Buy $49
2026-01-23 init Roth Capital — → Buy $58
2026-01-05 init TD Cowen — → Buy $67
2025-12-19 main HC Wainwright & Co. Buy → Buy $47
2025-11-19 init BTIG — → Buy $40
2025-08-13 reit HC Wainwright & Co. Buy → Buy $36
2025-04-09 init HC Wainwright & Co. — → Buy $36
2024-12-09 init Alliance Global Partners — → Buy $35
News
RSS: Latest VTVT news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-09-22 AKKARAJU SRINIVAS Director — 106,000 $22.17 $2,349,713
2025-09-03 BAKER BROS ADVISORS, L.P. Unknown — 51,000 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
-100.00%
1.02
0.00
-100.00%
2.02
Operating Revenue
0.00
-100.00%
1.02
0.00
-100.00%
2.02
Operating Expense
32.81
+30.21%
25.20
-1.20%
25.50
+3.84%
24.56
Research And Development
17.86
+54.69%
11.55
-15.07%
13.60
+10.02%
12.36
Selling General And Administration
14.95
+9.49%
13.65
+14.65%
11.91
-2.41%
12.20
General And Administrative Expense
14.95
+9.49%
13.65
+14.65%
11.91
-2.41%
12.20
Other Gand A
14.95
+9.49%
13.65
+14.65%
11.91
-2.41%
12.20
Total Expenses
32.81
+30.21%
25.20
-1.20%
25.50
+3.84%
24.56
Operating Income
-32.81
-35.68%
-24.18
+5.18%
-25.50
-13.14%
-22.54
Total Operating Income As Reported
-32.81
-35.68%
-24.18
+5.18%
-25.50
-13.14%
-22.54
EBITDA
-31.06
-37.94%
-22.52
+12.94%
-25.86
-4.43%
-24.77
Normalized EBITDA
-31.06
-37.94%
-22.52
+12.94%
-25.86
-4.43%
-24.77
Reconciled Depreciation
0.02
-82.02%
0.09
-1.11%
0.09
-2.17%
0.09
EBIT
-31.07
-37.47%
-22.61
+12.90%
-25.95
-4.41%
-24.86
Net Income
-26.97
-46.11%
-18.46
+8.83%
-20.25
-5.67%
-19.16
Pretax Income
-31.08
-37.49%
-22.61
+12.94%
-25.97
-4.39%
-24.87
Net Non Operating Interest Income Expense
1.86
+19.11%
1.56
+240.96%
0.46
+36.20%
0.34
Interest Expense Non Operating
0.01
0.00
-100.00%
0.01
-13.33%
0.01
Net Interest Income
1.86
+19.11%
1.56
+240.96%
0.46
+36.20%
0.34
Interest Expense
0.01
0.00
-100.00%
0.01
-13.33%
0.01
Interest Income Non Operating
1.87
+19.49%
1.56
+231.57%
0.47
+34.09%
0.35
Interest Income
1.87
+19.49%
1.56
+231.57%
0.47
+34.09%
0.35
Other Income Expense
-0.14
-1460.00%
0.01
+101.08%
-0.92
+65.43%
-2.67
Other Non Operating Income Expenses
-0.14
-1460.00%
0.01
+101.08%
-0.92
+65.43%
-2.67
Tax Provision
0.00
-100.00%
0.10
0.00
-100.00%
0.20
Tax Rate For Calcs
0.00
-100.00%
0.00
0.00
-100.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-31.08
-36.89%
-22.70
+12.56%
-25.97
-3.56%
-25.07
Net Income From Continuing Operation Net Minority Interest
-26.97
-46.11%
-18.46
+8.83%
-20.25
-5.67%
-19.16
Net Income From Continuing And Discontinued Operation
-26.97
-46.11%
-18.46
+8.83%
-20.25
-5.67%
-19.16
Net Income Continuous Operations
-31.08
-36.89%
-22.70
+12.56%
-25.97
-3.56%
-25.07
Minority Interests
4.11
-3.23%
4.24
-25.77%
5.72
-3.27%
5.91
Normalized Income
-26.97
-46.11%
-18.46
+8.83%
-20.25
-5.67%
-19.16
Net Income Common Stockholders
-26.97
-46.11%
-18.46
+8.83%
-20.25
-5.67%
-19.16
Diluted EPS
-3.20
+0.00%
-3.20
+67.04%
-9.71
+6.63%
-10.40
Basic EPS
-3.20
+0.00%
-3.20
+67.04%
-9.71
+6.63%
-10.40
Basic Average Shares
8.42
+45.96%
5.77
+176.79%
2.08
+11.38%
1.87
Diluted Average Shares
8.42
+45.96%
5.77
+176.79%
2.08
+11.38%
1.87
Diluted NI Availto Com Stockholders
-26.97
-46.11%
-18.46
+8.83%
-20.25
-5.67%
-19.16
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
89.90
+134.93%
38.27
+247.30%
11.02
-66.85%
33.24
Current Assets
89.89
+135.86%
38.11
+257.63%
10.66
-60.67%
27.09
Cash Cash Equivalents And Short Term Investments
88.93
+142.02%
36.75
+289.01%
9.45
-22.10%
12.13
Cash And Cash Equivalents
88.93
+142.02%
36.75
+289.01%
9.45
-22.10%
12.13
Receivables
—
0.06
-39.22%
0.10
-99.18%
12.42
Accounts Receivable
—
0.06
-39.22%
0.10
-41.04%
0.17
Prepaid Assets
0.74
-37.67%
1.19
+7.48%
1.11
-56.54%
2.55
Current Deferred Assets
—
—
—
0.00
Other Current Assets
0.22
+24.57%
0.17
—
—
Total Non Current Assets
0.01
-96.08%
0.15
-57.62%
0.36
-94.12%
6.14
Net PPE
—
0.15
-57.62%
0.36
-35.07%
0.56
Gross PPE
—
0.66
-22.05%
0.85
-11.02%
0.95
Accumulated Depreciation
—
-0.51
-4.31%
-0.49
-22.67%
-0.40
Properties
—
0.00
0.00
0.00
Buildings And Improvements
—
—
0.24
-30.09%
0.35
Machinery Furniture Equipment
—
0.13
-34.34%
0.20
+0.00%
0.20
Other Properties
—
0.12
-48.77%
0.24
-30.09%
0.35
Leases
—
0.41
+0.00%
0.41
+0.00%
0.41
Investments And Advances
—
—
0.00
-100.00%
5.59
Long Term Equity Investment
—
—
0.00
-100.00%
5.59
Other Non Current Assets
0.01
-96.08%
0.15
—
—
Total Liabilities Net Minority Interest
25.46
+6.25%
23.96
-18.95%
29.57
+7.91%
27.40
Current Liabilities
6.64
+27.81%
5.20
-51.07%
10.62
+37.77%
7.71
Payables And Accrued Expenses
4.48
+27.23%
3.52
-59.91%
8.78
+34.50%
6.53
Payables
1.13
+20.55%
0.94
-76.96%
4.08
+65.58%
2.46
Accounts Payable
1.13
+20.55%
0.94
-76.96%
4.08
+65.58%
2.46
Current Accrued Expenses
3.34
+29.66%
2.58
-45.14%
4.70
+15.67%
4.06
Pensionand Other Post Retirement Benefit Plans Current
2.08
+37.91%
1.51
+2.93%
1.47
+86.04%
0.79
Current Debt And Capital Lease Obligation
—
0.17
-53.06%
0.36
-4.76%
0.38
Current Debt
—
—
0.19
-14.73%
0.22
Other Current Borrowings
—
—
0.19
-14.73%
0.22
Current Capital Lease Obligation
0.00
-100.00%
0.17
+0.00%
0.17
+9.74%
0.15
Current Deferred Liabilities
—
0.00
-100.00%
0.02
+0.00%
0.02
Current Deferred Revenue
—
0.00
-100.00%
0.02
+0.00%
0.02
Other Current Liabilities
0.08
—
—
—
Total Non Current Liabilities Net Minority Interest
18.82
+0.28%
18.77
-0.94%
18.95
-3.77%
19.69
Long Term Debt And Capital Lease Obligation
—
0.00
-100.00%
0.17
-50.00%
0.34
Long Term Capital Lease Obligation
—
0.00
-100.00%
0.17
-50.00%
0.34
Non Current Deferred Liabilities
18.67
+0.00%
18.67
+0.00%
18.67
+0.00%
18.67
Non Current Deferred Revenue
18.67
+0.00%
18.67
+0.00%
18.67
+0.00%
18.67
Preferred Securities Outside Stock Equity
—
—
—
16.58
Stockholders Equity
64.44
+428.22%
12.20
+149.43%
-24.68
-129.80%
-10.74
Common Stock Equity
64.44
+428.22%
12.20
+149.43%
-24.68
-129.80%
-10.74
Capital Stock
0.04
+21.88%
0.03
+18.52%
0.03
+0.00%
0.03
Common Stock
0.04
+21.88%
0.03
+18.52%
0.03
+0.00%
0.03
Share Issued
3.94
+50.78%
2.61
+25.29%
2.08
+2.35%
2.04
Ordinary Shares Number
3.94
+50.78%
2.61
+25.29%
2.08
+2.35%
2.04
Additional Paid In Capital
391.09
+25.40%
311.88
+21.67%
256.33
+0.62%
254.76
Retained Earnings
-326.69
-9.00%
-299.72
-6.65%
-281.04
-5.84%
-265.52
Minority Interest
0.00
-100.00%
2.10
-65.72%
6.13
-63.02%
16.58
Total Equity Gross Minority Interest
64.44
+350.58%
14.30
+177.10%
-18.55
-417.67%
5.84
Total Capitalization
64.44
+428.22%
12.20
+149.43%
-24.68
-129.80%
-10.74
Working Capital
83.25
+152.91%
32.92
+86523.68%
0.04
-99.80%
19.39
Invested Capital
64.44
+428.22%
12.20
+149.81%
-24.49
-132.87%
-10.52
Total Debt
0.00
-100.00%
0.17
-68.05%
0.53
-26.12%
0.72
Capital Lease Obligations
0.00
-100.00%
0.17
-50.00%
0.34
-31.30%
0.49
Net Tangible Assets
64.44
+428.22%
12.20
+149.43%
-24.68
-129.80%
-10.74
Tangible Book Value
64.44
+428.22%
12.20
+149.43%
-24.68
-129.80%
-10.74
Derivative Product Liabilities
0.15
+52.00%
0.10
-9.09%
0.11
-83.92%
0.68
Notes Receivable
—
—
0.00
-100.00%
12.24
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-25.25
+0.21%
-25.31
-32.63%
-19.08
-19.09%
-16.02
Cash Flow From Continuing Operating Activities
-25.25
+0.21%
-25.31
-32.63%
-19.08
-19.09%
-16.02
Net Income From Continuing Operations
-31.08
-36.89%
-22.70
+12.56%
-25.97
-3.56%
-25.07
Depreciation Amortization Depletion
0.02
-82.02%
0.09
-1.11%
0.09
-2.17%
0.09
Depreciation
0.02
-82.02%
0.09
-1.11%
0.09
-2.17%
0.09
Depreciation And Amortization
0.02
-82.02%
0.09
-1.11%
0.09
-2.17%
0.09
Other Non Cash Items
—
—
0.21
+163.20%
-0.34
Stock Based Compensation
3.77
+36.92%
2.76
+74.71%
1.58
+24.06%
1.27
Asset Impairment Charge
0.00
0.00
-100.00%
4.25
0.00
Operating Gains Losses
0.14
+1520.00%
-0.01
+99.72%
-3.63
-284.25%
-0.95
Gain Loss On Investment Securities
0.14
+1460.00%
-0.01
+98.26%
-0.57
+39.32%
-0.95
Unrealized Gain Loss On Investment Securities
—
0.00
0.00
-100.00%
3.58
Gain Loss On Sale Of PPE
0.01
0.00
0.00
—
Change In Working Capital
1.89
+134.79%
-5.44
-223.76%
4.39
-18.40%
5.38
Change In Receivables
—
0.04
-43.66%
0.07
+161.21%
-0.12
Changes In Account Receivables
—
0.04
-43.66%
0.07
+161.21%
-0.12
Change In Prepaid Assets
0.45
+307.87%
-0.22
-113.93%
1.55
+484.86%
-0.40
Change In Payables And Accrued Expense
1.53
+129.34%
-5.21
-278.05%
2.93
+442.17%
-0.86
Change In Accrued Expense
—
—
—
0.00
Change In Payable
—
—
—
-0.86
Change In Account Payable
—
—
—
-0.86
Change In Other Working Capital
—
-0.02
—
6.76
Change In Other Current Assets
0.08
-54.19%
0.18
+163.24%
0.07
0.00
Change In Other Current Liabilities
-0.17
+0.00%
-0.17
-9.74%
-0.15
0.00
Investing Cash Flow
0.00
0.00
-100.00%
4.40
+21071.43%
-0.02
Cash Flow From Continuing Investing Activities
0.00
0.00
-100.00%
4.40
+21071.43%
-0.02
Net PPE Purchase And Sale
—
0.00
0.00
+100.00%
-0.02
Purchase Of PPE
—
0.00
0.00
+100.00%
-0.02
Capital Expenditure
—
—
—
-0.02
Net Business Purchase And Sale
0.00
0.00
-100.00%
4.40
0.00
Gain Loss On Sale Of Business
0.00
0.00
+100.00%
-3.06
0.00
Financing Cash Flow
77.44
+47.21%
52.61
+338.50%
12.00
-18.69%
14.75
Cash Flow From Continuing Financing Activities
77.44
+47.21%
52.61
+338.50%
12.00
-18.69%
14.75
Net Issuance Payments Of Debt
0.00
+100.00%
-0.19
-478.79%
-0.03
-3.13%
-0.03
Issuance Of Debt
0.39
0.00
-100.00%
0.57
-27.06%
0.78
Repayment Of Debt
-0.39
-105.24%
-0.19
+68.11%
-0.60
+25.87%
-0.81
Long Term Debt Issuance
0.39
0.00
-100.00%
0.57
-27.06%
0.78
Long Term Debt Payments
—
—
-0.60
+25.87%
-0.81
Net Long Term Debt Issuance
0.39
0.00
-100.00%
0.57
-27.06%
0.78
Short Term Debt Payments
-0.39
-105.24%
-0.19
+68.11%
-0.60
+25.87%
-0.81
Net Short Term Debt Issuance
-0.39
-105.24%
-0.19
+68.11%
-0.60
+25.87%
-0.81
Net Common Stock Issuance
77.48
+46.74%
52.80
+338.89%
12.03
-18.64%
14.79
Proceeds From Stock Option Exercised
0.02
0.00
0.00
-100.00%
9.75
Net Other Financing Charges
-0.05
—
—
—
Changes In Cash
52.19
+91.16%
27.30
+1118.66%
-2.68
-107.91%
-1.29
Beginning Cash Position
36.75
+289.01%
9.45
-22.10%
12.13
-9.61%
13.41
End Cash Position
88.93
+142.02%
36.75
+289.01%
9.45
-22.10%
12.13
Free Cash Flow
-25.25
+0.21%
-25.31
-32.63%
-19.08
-18.94%
-16.04
Interest Paid Supplemental Data
0.01
+200.00%
0.00
-85.71%
0.01
-6.67%
0.01
Income Tax Paid Supplemental Data
0.00
-100.00%
0.10
0.00
-100.00%
0.20
Change In Interest Payable
—
—
—
0.00
Common Stock Issuance
77.48
+46.74%
52.80
+338.89%
12.03
-18.64%
14.79
Issuance Of Capital Stock
77.48
+46.74%
52.80
+338.89%
12.03
-18.64%
14.79
Sale Of Business
0.00
0.00
-100.00%
4.40
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category